facioscapulohumeral muscular dystrophy
facioscapulohumeral muscular dystrophy
Explore linked clinical trials. Standard reference: MONDO:000134729 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07798609 | |
| Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Enrolling by invitation | Phase 1 / Phase 2 | 2026-10-05 | NCT06131983 | |
| A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05548556 | |
| Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Not stated | 2026-09-17 | NCT03458832 | |
| Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 2 | 2026-09-02 | NCT07435129 | |
| The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Not stated | 2026-08-20 | NCT04001582 | |
| A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT06907875 | |
| Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Not stated | 2026-08-05 | NCT01671865 | |
| A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 3 | 2026-07-27 | NCT07038200 | |
| Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, frontometaphyseal dysplasia 2, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, progressive muscular dystrophy | Active, not recruiting | Phase 2 | 2026-07-14 | NCT06547216 | |
| Personalized Training for People With Rare Neuromuscular Disorders | Charcot-Marie-Tooth disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, central nervous system malformation, facioscapulohumeral muscular dystrophy, hereditary disease, hereditary motor and sensory neuropathy, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy | Recruiting | Not applicable | 2026-06-18 | NCT06708468 | |
| Amino Acids and Exercise in FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Not applicable | 2026-04-21 | NCT07543016 | |
| Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Charcot-Marie-Tooth disease, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Infections, Lambert-Eaton myasthenic syndrome, Lysosomal Storage Diseases, Nervous System, Muscular Disorders, Atrophic, Neoplasms by Site, Neuroinflammatory Diseases, Nutritional and Metabolic Diseases, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Picornaviridae infectious disease, RNA Virus Infections, TDP-43 proteinopathy, amyotrophic lateral sclerosis, autoimmune disease, autoimmune disorder of the nervous system, autonomic nervous system disorder, brain disorder, central nervous system disorder, central nervous system infectious disorder, central nervous system malformation, centronuclear myopathy, chronic inflammatory demyelinating polyradiculoneuropathy, congenital structural myopathy, demyelinating disease, disorder of glycogen metabolism, enterovirus infectious disease, facioscapulohumeral muscular dystrophy, glycogen storage disease II, hereditary disease, hereditary motor and sensory neuropathy, hereditary spastic paraplegia, immune system disorder, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inborn mitochondrial metabolism disorder, inborn mitochondrial myopathy, inclusion body myositis, inherited neurodegenerative disorder, lateral sclerosis, lysosomal storage disease, metabolic disease, motor neuron disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myasthenia gravis, myelitis, myositis disease, nemaline myopathy, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, orthostatic intolerance, paraneoplastic syndrome, peripheral nervous system disorder, poliomyelitis, polyneuropathy, polyradiculoneuropathy, postpoliomyelitis syndrome, primary dysautonomia, progressive muscular atrophy, proteostasis deficiencies, spinal cord disorder, spinal muscular atrophy, viral infectious disease | Recruiting | Not applicable | 2026-03-17 | NCT07478172 | |
| Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular Dystrophies | facioscapulohumeral muscular dystrophy | Recruiting | Not applicable | 2026-03-03 | NCT06600308 | |
| Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Not stated | 2026-02-25 | NCT06847282 | |
| Clenbuterol to Target DUX4 in FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 | 2026-02-25 | NCT06721299 | |
| BetterLife FSHD: A Patient-driven Health and Research Platform | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Not stated | 2026-02-20 | NCT07409142 | |
| Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 | 2025-12-08 | NCT07086521 | |
| Biomarker Development for Muscular Dystrophies | Becker muscular dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, facioscapulohumeral muscular dystrophy, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Recruiting | Not stated | 2025-11-24 | NCT05019625 | |
| Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, Myotonic Dystrophy 2, facioscapulohumeral muscular dystrophy, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic dystrophy type 1, myotonic dystrophy type 2, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Recruiting | Not stated | 2025-10-15 | NCT00082108 | |
| ADVANCED FSHD-COM: New Clinical Outcome Measures to Evaluate Non-ambulant FSHD Patients, a Pilot Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Not applicable | 2025-09-25 | NCT05453461 | |
| Imaging and Gait Analysis in FSHD Patients | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Enrolling by invitation | Not stated | 2025-09-10 | NCT07164937 | |
| Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Friedreich ataxia, Guillain-Barre syndrome, Lambert-Eaton myasthenic syndrome, Lysosomal Storage Diseases, Nervous System, Muscular Disorders, Atrophic, Neoplasms by Site, Nutritional and Metabolic Diseases, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, Spinocerebellar Degenerations, TDP-43 proteinopathy, amyotrophic lateral sclerosis, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, central nervous system disorder, central nervous system malformation, cerebellar disorder, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, disorder of glycogen metabolism, facioscapulohumeral muscular dystrophy, glycogen storage disease II, hereditary disease, hereditary motor and sensory neuropathy, immune system disorder, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inborn mitochondrial metabolism disorder, inclusion body myositis, inherited neurodegenerative disorder, lysosomal storage disease, metabolic disease, motor neuron disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myasthenia gravis, myositis disease, myotonic dystrophy, myotonic syndrome, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy, proteostasis deficiencies, spinal cord disorder, spinal muscular atrophy | Enrolling by invitation | Not stated | 2025-09-10 | NCT06605612 | |
| Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology | Body Weight, Charcot-Marie-Tooth disease, Cognition Disorders, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, Lambert-Eaton myasthenic syndrome, Muscular Disorders, Atrophic, Neoplasms by Site, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Overweight, Paraneoplastic Syndromes, Nervous System, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Spinocerebellar Ataxias, Spinocerebellar Degenerations, atactic disorder, non-human animal, autoimmune disease, autoimmune disorder of the nervous system, basal ganglia disorder, brain disorder, central nervous system disorder, central nervous system malformation, cerebellar ataxia, cerebellar disorder, choreatic disease, cognitive disorder, cranial nerve neuropathy, dementia, eye disorder, facioscapulohumeral muscular dystrophy, hereditary disease, hereditary motor and sensory neuropathy, hereditary spastic paraplegia, immune system disorder, inherited neurodegenerative disorder, movement disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myasthenia gravis, myotonic dystrophy, myotonic syndrome, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, nutritional disorder, obesity disorder, ophthalmoplegia, overnutrition, palsy, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, psychiatric disorder, spinal cord disorder, tauopathy | Recruiting | Not applicable | 2025-08-22 | NCT07136844 | |
| The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Friedreich ataxia, Guillain-Barre syndrome, Lambert-Eaton myasthenic syndrome, Lysosomal Storage Diseases, Nervous System, Muscular Disorders, Atrophic, Myotonic Dystrophy 2, Neoplasms by Site, Nutritional and Metabolic Diseases, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, Spinocerebellar Degenerations, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, central nervous system disorder, central nervous system malformation, cerebellar disorder, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, disorder of glycogen metabolism, facioscapulohumeral muscular dystrophy, glycogen storage disease II, hereditary disease, hereditary motor and sensory neuropathy, immune system disorder, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inborn mitochondrial metabolism disorder, inclusion body myositis, inherited neurodegenerative disorder, limb-girdle muscular dystrophy, lysosomal storage disease, metabolic disease, motor neuron disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myasthenia gravis, myositis disease, myotonic dystrophy, myotonic syndrome, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy, spinal cord disorder, spinal muscular atrophy | Enrolling by invitation | Not applicable | 2025-07-18 | NCT07072676 |